New research article in The Lancet HIV>

Efficacy, safety, and tolerability of switching to long-acting #cabotegravir plus #rilpivirine versus continuing fixed-dose #bictegravir, #emtricitabine, and #tenofovir alafenamide in virologically suppressed adults with #HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00136-4/fulltext